Previously, drug therapy for hemangioma was limited to corticosteroids, but its application was somewhat restricted due to the systemic reactions of hormones and the national resistance to hormones. It is a non-selective beta-blocker, which is mostly used for the treatment of arrhythmia, angina pectoris, hypertension, hyperthyroidism, hypertrophic cardiomyopathy and pheochromocytoma. For the first time, it was reported that cardiotrophin caused the tumor of hemangioma to become smaller in extent, darker in color, flatter and softer in texture. This effect was discovered accidentally when it was used to treat 2 children with heart disease combined with facial hemangioma. Once reported, a series of clinical and basic studies on the treatment of hemangiomas in infants and children were rapidly conducted in various countries. Scholars both at home and abroad have used it for the treatment of infantile hemangiomas in different parts of the body and have achieved good results. At present, the ideal standard for the treatment of hemangioma is to control its growth, but also to promote its regression, but also to protect the patient’s appearance, and the oral use of insulin can achieve such an effect, and insulin is better tolerated, compared with systemic steroids have fewer side effects, so insulin gradually become the first-line drugs for the treatment of infant and young children hemangioma. Prior to the application of the drug, routine blood tests (routine blood, liver and kidney function, blood glucose) and cardiac-related tests (echocardiography, electrocardiogram) should be performed to rule out contraindications to the use of the drug. After the start of drug administration, children should be kept in the hospital for 2 days for observation and review of relevant indexes for early detection of possible side effects caused by drugs, including circulatory system: bradycardia, hypotension, cardiogenic shock, atrioventricular block, etc.; endocrine and metabolic system: hypoglycemia, hyperkalemia, hypothyroidism, etc.; respiratory system: bronchial asthma, pulmonary edema, etc.; digestive system: nausea, diarrhea, constipation or abdominal distension, etc. Therefore, during the initial stage of treatment, the child’s heart rate, blood pressure and blood glucose level should be closely monitored. After stabilization, the child can take the medication outside the hospital and be reviewed regularly at the outpatient clinic. Usually the medication course is 4-6 months, and the dose is 1-1.5mg/kg.d. The medication is divided into three doses a day, and the changes in heart rate and blood glucose are most obvious 1-3 hours after medication. The dose of the drug should be updated according to the weight of the child, and the heart rate and blood glucose should be monitored early after the dose is changed.